Kyowa Hakko Kirin has formed another alliance to advance its drug discovery programs, this time focused on fragment-based discovery and featuring NovAliX.
The companies will collaborate to develop drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
For its efforts NovAliX will receive technology access fees as well as further research funding payments and milestones.
Kyowa Hakko Kirin has inked a number of alliances in the last six months. In November it partnered with Activiomics, which is applying its TIQUAS phosphoproteomics platform to elucidate signaling mechanisms of lead compounds in relevant cell-based systems.
In June, Kyowa partnered with Otsuka to advance its diabetes and oncology programs.